Amgen Inc. stock (US0311621009): shares hover in mid-330 USD range as market digests Q1 2026 beat and R&D push

Amgen Inc. shares on Nasdaq traded roughly flat around the mid-330 USD area at the end of May 2026, as U.S. investors weighed a solid Q1 2026 earnings beat against a pullback in April and the biotech group’s USD 125 million expansion of its South San Francisco small-molecule research hub.

Amgen Inc. shares on the Nasdaq in the United States have been changing hands in a relatively narrow band around the mid-330 USD level in recent sessions, with the stock closing at about USD 336.79 on 05/29/2026 according to MarketBeat data cited by Ad-hoc-news as of 05/31/2026, leaving the U.S. biotech group broadly steady after a volatile response to its latest quarterly results and research spending plans.

The stock traded at roughly USD 336 to 337 on 05/29/2026 on Nasdaq, according to Ad-hoc-news referencing MarketBeat as of 05/31/2026, situating the shares well within their 52-week corridor of approximately USD 268 to USD 391 and signaling that the market is still digesting Amgen’s Q1 2026 numbers and capital allocation for pipeline expansion.

As of: 01/06/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: Amgen
• Sector/industry: Biotechnology and biopharmaceuticals
• Headquarters/country: Thousand Oaks, United States
• Core markets: United States, Europe, selected international markets
• Key revenue drivers: Products for oncology, inflammation, bone health and other specialty therapeutic areas
• Home exchange/listing venue: Nasdaq (AMGN)
• Trading currency: USD

Amgen Inc.: core business model

Amgen focuses on discovering, developing and commercializing innovative biological and small-molecule medicines, with sales concentrated in chronic and specialty diseases such as cancer, inflammatory conditions and bone disorders.

What banks and research houses say about Amgen Inc.

Analyst coverage of Amgen remains active in the United States, with brokers updating their views around the Q1 2026 earnings report, even if individual rating changes were not disclosed in detail in the latest public summaries. According to MarketBeat data referenced in a 05/31/2026 note on institutional holdings, the stock carried an average rating of "Hold" with a consensus price target of about USD 355.19 as of late May 2026, implying that many analysts see moderate upside relative to the mid-330 USD trading range but are not uniformly positive on near-term performance.

A separate review of sector commentary by Barchart on 05/31/2026 highlighted that Amgen’s shares fell about 4.8 percent in immediate reaction to the Q1 2026 release on 04/30/2026 despite the company reporting adjusted earnings per share of USD 5.15, above the USD 4.77 consensus, and revenue growth of roughly 6 percent year-on-year, underscoring how sentiment is balancing earnings delivery with expectations around the pipeline, obesity treatments and competitive dynamics in the wider U.S. healthcare sector.

Conclusion

Amgen Inc. shares on Nasdaq are currently trading in a fairly stable pattern around the mid-330 USD mark as U.S. investors mull a Q1 2026 earnings beat and the implications of a pullback that followed the April release. The mix of a consensus "Hold" rating and a price target around USD 355, alongside ongoing debate about Amgen’s obesity and small-molecule strategies, suggests that the market is waiting for clearer catalysts from the pipeline and further updates on capital deployment to break the stock out of its present range.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.